Agreement enables Biohaven to exercise option on up to three of Artizan’s candidates for the treatment of inflammatory bowel disease… Read More
– COSELA is the only FDA-approved therapy that helps proactively deliver multilineage myeloprotection to patients with extensive-stage small cell lung cancer being treated with chemotherapy –… Read More
Exclusive license for Asia (ex-Japan), Australia and New Zealand; Parties plan to conduct combination studies with BeiGene’s anti-PD-1 antibody tislelizumab BOSTON & CAMBRIDGE, Mass. & BEIJING–(BUSINESS WIRE)–Feb. 17, 2021– Boston Immune Technologies and Therapeutics,… Read More
BIAL Biotech to be based in Cambridge, Massachusetts and will be a ResearchCenter of Excellence dedicated to genetically-defined Parkinson’s disease• LTI-291 clinical program and other… Read More
WATERTOWN, Mass., Aug. 20, 2020 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a… Read More
Phase 1/2 “INTREPID” trial to evaluate safety and ability of engineered FGF-1 to regenerate corneal endothelial cells August 19, 2020 07:00 AM Eastern Daylight… Read More
Therapy currently being evaluated in Phase I/II clinical study Company formed with $8.15 million Series 1; led by founding investors Hatteras Venture Partners and the… Read More
– Kymera to receive $150 million upfront with more than $2 billion in potential milestones plus royalty payments – – Kymera to retain option during clinical development… Read More
Financing will advance two ARC™ clinical programs and expand pipeline development — DURHAM, NC and AUSTIN, TX – June 15, 2020 – Shattuck… Read More
PhaseBio receives clearance of IND application from U.S. FDA under Coronavirus Treatment Acceleration Program (CTAP) “VANGARD” trial will assess the efficacy and safety of PB1046… Read More